Endometriosis: Functional Medicine, Herbal, and Integrative Approaches

An Evidence-Based Review for the Integrative Clinician

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Yoon Hang Kim, MD, MPH, is board-certified in preventive medicine and has practiced integrative and functional medicine for more than 20 years. He completed the University of Arizona Osher Fellowship in Integrative Medicine under Dr. Andrew Weil and holds medical acupuncture certification from UCLA. He has directed the Integrative Medicine Program at the University of Kansas Medical Center, served as Medical Director of Integrative Oncology at Miami Cancer Institute, and served as Enterprise Medical Director at WellMed/Optum, where he built a non-opioid integrative pain program for Medicare Advantage members.

His clinical focus includes low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 8 books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com  | 

Clinical: www.directintegrativecare.com

Key Points

• Integrative care in endometriosis is best positioned as an adjunct to gynecologic management, not a replacement for hormonal therapy, surgery, or fertility care.
• The strongest direct adjunct evidence is symptom-specific: a low-FODMAP diet for gastrointestinal symptoms and CBT for pain-related quality of life.
• Acupuncture and pelvic floor physiotherapy show positive but limited-certainty evidence; several supplements and botanicals have preliminary, conflicting, or observational support only.
• No nutritional or botanical intervention has been shown to reliably regress lesions or improve live-birth rates.
• Evidence certainty, mechanistic plausibility, and clinical usefulness are separate judgments and should be reported separately for each outcome.

Introduction

Endometriosis affects roughly 10% of women of reproductive age worldwide, yet the average diagnostic delay stretches seven to ten years from symptom onset. The disease is defined by ectopic endometrial-like tissue that drives chronic inflammation, estrogen-dependent lesion growth, and a pain experience that often exceeds what lesion burden alone would predict. Conventional management — hormonal suppression, analgesics, and surgical excision — remains the backbone of treatment, but many patients experience incomplete relief, intolerable side effects, medication fatigue, or fertility constraints that make long-term hormonal therapy impractical.

These unmet needs have driven strong patient and clinician interest in complementary, alternative, and integrative medicine (CAIM) approaches. A 2025 scoping review across PubMed and PsycINFO analyzed 107 studies spanning acupuncture, Chinese and natural medicine, nutritional supplements, physical therapy, dietary interventions, relaxation techniques, and psychotherapy, reporting that acupuncture, herbal medicine, and nutritional supplements had the largest evidence base. A scoping review maps the volume of literature, however; it does not establish treatment certainty, which this chapter assesses outcome by outcome.

Functional medicine contributes a systems-oriented framework that asks why a particular patient's disease behaves the way it does — examining nutritional status, gut function, inflammatory load, hormonal metabolism, and central pain processing as modifiable upstream variables. At its best, this approach targets diet, bowel symptoms, pain amplification, oxidative stress, and quality of life alongside appropriate gynecologic treatment. At its worst, it drifts into unsubstantiated root-cause claims, oversized supplement stacks, and replacement of evidence-based gynecologic care.

This chapter reviews the current evidence for integrative and functional medicine strategies in endometriosis, distinguishing what has been tested in human clinical trials from what remains at the preclinical or hypothesis-generating stage. The intent is to give the integrative clinician an honest map of the landscape — where the signal is credible, where it is absent, and where the most promising research directions lie.

Pathophysiology Through an Integrative Lens

Endometriosis is not a single-mechanism disease, and framing it as such is where many functional medicine narratives go wrong. The pathophysiology involves at least five interlocking systems, each of which represents both a research frontier and a potential therapeutic target.

Estrogen Dependence and Local Aromatase Activity. Ectopic endometrial implants express aromatase, generating local estrogen production that fuels lesion growth independent of ovarian cycling. This observation underpins hormonal suppression strategies and makes estrogen metabolism — including hepatic conjugation, enterohepatic recirculation, and the gut microbiome's role in deconjugation — a biologically plausible area for integrative inquiry. However, demonstrating that a nutritional intervention modifies local tissue estrogen levels in a clinically meaningful way requires evidence well beyond a serum hormone panel.

Chronic Inflammation and Immune Dysregulation. Peritoneal fluid in endometriosis patients shows elevated concentrations of IL-1β, IL-6, IL-8, TNF-α, VEGF, and prostaglandin E2. Macrophage phenotype shifts, reduced NK cell cytotoxicity, and regulatory T-cell dysfunction all contribute to an environment where ectopic tissue survives immune surveillance. This inflammatory milieu is the mechanistic rationale behind anti-inflammatory dietary patterns, omega-3 fatty acids, curcumin, and antioxidant supplementation — though mechanistic plausibility is not the same as demonstrated clinical benefit.

Oxidative Stress. Reactive oxygen species accumulate in the peritoneal environment and contribute to DNA damage, lipid peroxidation, and pain sensitization. Iron deposition from retrograde menstruation generates further oxidative load. Antioxidant supplementation has been tested clinically: one 2024 meta-analysis of five RCTs reported reduced chronic pelvic pain, dysmenorrhea, and dyspareunia with combined vitamin C and E, although other pooled analyses conflict (see Nutritional Supplements). Plasma malondialdehyde (MDA) levels, a marker of lipid peroxidation, decreased in proportion to supplementation duration.

Central Sensitization and Neuroplasticity. Endometriosis is increasingly recognized as a chronic pain condition with a central nervous system component. Prolonged nociceptive input from pelvic lesions drives spinal cord wind-up, descending facilitation, and cortical reorganization. Patients may develop widespread hyperalgesia, visceral cross-sensitization, and comorbid conditions including IBS-like symptoms, bladder pain, and migraine. This framework offers one explanation — among several, including residual or deep disease, adhesions, and pelvic floor dysfunction — for why lesion removal does not always resolve pain, and it makes psychological interventions, pain neuroscience education, and pelvic floor physiotherapy relevant as symptom-directed and functional therapies, without implying they modify disease biology.

The Microbiome–Estrobolome Connection. The estrobolome — the collection of gut bacterial genes capable of metabolizing estrogens via β-glucuronidase and related enzymes — has emerged as a hypothesis linking gut health to estrogen-dependent disease. Dysbiosis could theoretically enhance enterohepatic estrogen recirculation, amplifying systemic estrogen exposure. However, the largest metagenome study to date — an Estonian cohort of 1,000 women including 136 with endometriosis — found no significant differences in estrobolome-associated enzyme reads between groups. Smaller studies have reported altered Bacillota-to-Bacteroidota ratios and shifts in vaginal community state types, but standardization problems across microbiome research make these findings difficult to translate into clinical recommendations. The estrobolome hypothesis remains biologically interesting but clinically unproven as a driver of endometriosis pathogenesis.

Dietary Interventions

Mediterranean-Style Eating. The Mediterranean dietary pattern — rich in vegetables, fruit, legumes, whole grains, nuts, olive oil, and fish — is the most commonly recommended foundation in integrative endometriosis care. Its anti-inflammatory profile is biologically plausible, and observational data suggests that higher adherence correlates with reduced systemic inflammatory markers. A 2025 review of medical nutrition therapy in endometriosis positioned the Mediterranean diet as the default for normal-weight patients. However, randomized trial evidence that this pattern specifically reduces endometriosis pain or lesion burden remains limited. The recommendation rests on general anti-inflammatory principles and population-level associations rather than disease-specific RCTs.

Clinicians should present this as a reasonable, sustainable dietary foundation — not as a targeted endometriosis treatment with predictable lesion-level effects.

The Low-FODMAP Diet for Gastrointestinal Symptoms. This is arguably the strongest dietary evidence specific to endometriosis. Gastrointestinal symptoms affect more than 75% of patients with endometriosis, and the overlap with IBS is so substantial that patients are three times more likely to meet Rome criteria for IBS than the general population.

The 2025 EndoFOD trial (Varney et al., Alimentary Pharmacology and Therapeutics) was a randomized, controlled, single-blinded crossover feeding study in 35 women with endometriosis and poorly controlled GI symptoms. After 28 days, 60% responded to the low-FODMAP diet (less than 5 g/day FODMAPs) versus 26% on the control diet (approximately 20 g/day FODMAPs based on Australian Dietary Guidelines). Improvements reached clinical significance by week two and continued to improve throughout the intervention period. Specifically, overall GI symptom scores dropped to 35 mm on the low-FODMAP diet versus 58 mm on the control diet (on a 100 mm scale), with significant benefits for abdominal pain, bloating, stool form, and quality of life on both GI-specific and endometriosis-specific scales.

The critical clinical distinction: this diet targets gastrointestinal symptoms, not the endometriotic lesions themselves. It should be implemented as a structured three-step process — restriction, reintroduction, personalization — under dietitian guidance to avoid unnecessary long-term restriction and nutritional inadequacy. An ongoing RCT at the University of São Paulo is combining the low-FODMAP diet with probiotics in 74 women with endometriosis and IBS, which may further clarify the interaction between fermentable carbohydrate reduction and microbiome modulation.

The Ketogenic Diet. A 2025 randomized trial (Naeini et al., BMC Women's Health 25:232) tested a 12-week MCT-modified ketogenic diet as an adjunct to standard treatment in 50 women, with 44 completing. Between-group improvements were seen for dyspareunia and dyschezia; pelvic pain did not reach conventional statistical significance (p = 0.07), and all attrition occurred in the intervention arm. Notably, participants had a BMI of 21–25, so this trial does not support framing the ketogenic diet primarily as an obesity-targeted endometriosis strategy. A separate 2025 review in Current Obesity Reports (Barrea et al.) discussed the ketogenic diet as a short-term metabolic tool, with the mechanistic rationale centering on ketone-mediated NLRP3 inflammasome suppression and improved insulin sensitivity. This should be classified as preliminary adjunctive evidence with substantial limitations — supervised, short-term use only — not an established endometriosis protocol.

Elimination Diets: Gluten-Free and Dairy-Free. Routine gluten-free or dairy-free diets are not supported for all patients with endometriosis. Individual intolerance or a concurrent diagnosis (celiac disease, lactose intolerance) may justify specific exclusions, but empiric broad elimination can create unnecessary nutritional restriction and food-related anxiety without predictable benefit. A 2025 scoping review in the Journal of Human Nutrition and Dietetics confirmed that the overall number of diet-intervention RCTs in endometriosis remains very small, and most existing data comes from uncontrolled studies.

Nutritional Supplements: Evidence Hierarchy

The supplement landscape for endometriosis is cluttered with products marketed on mechanistic rationale while lacking adequate human trial data. The following assessment distinguishes clinical trial evidence from biological plausibility.

N-Acetylcysteine (NAC). NAC is the most extensively studied single-agent nutraceutical for endometriosis. A 2026 PRISMA-compliant systematic review (Watrowski et al., Antioxidants 2026;15(7):880) analyzed six clinical studies alongside preclinical evidence. In non-postoperative settings, NAC was associated with reduced pain, decreased NSAID use, and endometrioma shrinkage or stabilization. Importantly, the same review reports a postoperative randomized comparison that found no added benefit over continuous oral contraceptive therapy for recurrence or pain — a result that belongs in any balanced NAC discussion. The most cited favorable data comes from a 2023 prospective single-cohort study (Anastasi et al., International Journal of Environmental Research and Public Health 20(6):4686) of 120 women receiving NAC 600 mg three times daily on three consecutive days each week — 1,800 mg on treatment days — for three months. Results showed statistically significant decreases in pain scores, endometrioma size, and serum CA-125 levels. Among the subgroup with reproductive desire, 75% achieved spontaneous pregnancy within six months, but this was an uncontrolled subgroup observation that cannot establish a fertility benefit.

The favorable pain, endometrioma, and fertility findings all come from uncontrolled designs — no placebo arm, no randomization, no blinding. The earlier Italian observational cohort (Porpora et al., 2013) similarly lacked placebo control. A registered phase III double-blind RCT at Royan Institute (NCT05460858) is designed to assess NAC's effects on oxidative stress markers and IVF/ICSI outcomes in patients with endometrioma; its current recruitment status is unverified and should not be presented as confirmed. The accurate framing is narrow: NAC's favorable pain and endometrioma claims rest on observational evidence, while the one postoperative RCT showed no advantage over oral contraceptive therapy. NAC has biological plausibility and encouraging observational signals, but cannot be described as a proven endometriosis treatment.

Vitamin C and Vitamin E. A 2024 meta-analysis of five placebo-controlled RCTs (Bayu and Wibisono, PLOS ONE) found that combined vitamin C and E supplementation was associated with significantly higher proportions of endometriosis patients reporting reduced chronic pelvic pain (RR 7.30; 95% CI 3.27–16.31), reduced dysmenorrhea (RR 1.96; 95% CI 1.25–3.07), and reduced dyspareunia (RR 5.08; 95% CI 2.10–12.26) compared to placebo. A separate 2023 meta-analysis of 13 RCTs involving 589 patients confirmed that vitamin E, with or without vitamin C, had a positive effect on chronic pelvic pain and that plasma MDA levels decreased in inverse proportion to supplementation dose and duration.

These favorable results need to be weighed against conflicting analyses. Another vitamin meta-analysis did not find a statistically significant pelvic-pain benefit for the combined C/E subgroup, and a broader placebo-controlled supplement review found no significant pooled pain benefit. The underlying trials were small and heterogeneous in dosing. Vitamin C and E are a reasonable adjunct to discuss, but the evidence is conflicting rather than established.

Vitamin D. Meta-analytic data on vitamin D supplementation for endometriosis pain has been mixed. The 2023 antioxidant vitamins meta-analysis found that vitamin D was associated with a trend toward pelvic pain reduction, but the difference did not reach statistical significance compared to placebo. Correcting a documented deficiency remains appropriate for its established clinical indications. Prescribing vitamin D specifically for endometriosis pain relief goes beyond what current trial data supports.

Omega-3 Fatty Acids. Despite strong mechanistic rationale, the pooled trial evidence for omega-3 supplementation in endometriosis has not established a pain benefit, and substantial heterogeneity limits interpretation. A 2025 meta-analysis of five RCTs involving 424 patients with endometriosis (published in Clinics, PROSPERO: CRD42023441699) found no statistically significant effects on pain (MD −0.387; 95% CI −1.742 to 0.967; I² = 93.3%), sexual activity, pain catastrophizing, or quality of life. However, omega-3 supplementation did significantly reduce inflammatory markers (MD −5.20; 95% CI −6.21 to −4.20; p < 0.001).

This pattern should be read cautiously. Inflammatory markers are surrogate outcomes, and small, heterogeneous trials can miss real clinical effects. The accurate statement is that the studied biomarker changes did not establish a corresponding clinical pain benefit — not that systemic anti-inflammatory activity is clinically irrelevant. Eating fish for overall health and prescribing fish oil as an endometriosis treatment remain different propositions.

Curcumin/Nanocurcumin. Curcumin's role is complicated by formulation-dependent results. A triple-blind placebo-controlled RCT of conventional curcumin 500 mg twice daily for eight weeks (Gudarzi et al., 2024, Phytotherapy Research) found no significant benefit for pain or quality of life. In contrast, a double-blind placebo-controlled RCT of nanocurcumin 80 mg/day added to dienogest for eight weeks (Sargazi-Taghazi et al., 2025, Phytomedicine) in 86 women with stage II–III endometriosis showed significantly greater improvement in dysmenorrhea (adjusted between-group difference −1.55; 95% CI −2.04 to −1.06), chronic pelvic pain (−1.55; 95% CI −2.04 to −1.06), and dyspareunia (−0.93; 95% CI −1.37 to −0.49). No significant endometrioma size reduction was seen.

The formulation distinction matters for reporting, but it should not be over-read. These were two separate trials, not a head-to-head comparison, so differences in background dienogest, population, sample size, and chance could all contribute to the divergent results. Better bioavailability is a plausible explanation, not an established one. The positive nanocurcumin trial is a single small short-term study that requires replication before clinical confidence is warranted. An additional triple-blind placebo-controlled curcumin trial for endometriosis dysmenorrhea (2025, Journal of Kerman University of Medical Sciences) adds to the curcumin-specific evidence base, though its full citation still requires verification.

Resveratrol. The cited pain trial (da Silva et al., 2017) tested resveratrol 40 mg/day for 42 days alongside a continuous combined oral contraceptive and found no superiority over contraceptive plus placebo for pain over the studied period. Other randomized resveratrol research has examined biological rather than pain outcomes, so this should not be described as the only resveratrol RCT. On present evidence, resveratrol should not be presented as a proven endometriosis pain treatment.

Herbal and Botanical Medicine

Herbal interventions occupy a wide evidence spectrum in endometriosis — from placebo-controlled RCTs to pure laboratory studies. Clinicians must distinguish agents with direct endometriosis trial data from those extrapolated from primary dysmenorrhea studies, animal models, or cell experiments.

Agents with Direct Endometriosis Clinical Evidence

Silymarin (Milk Thistle). A double-blind placebo-controlled trial (Mirzaei et al., 2022, Scientific Reports) enrolled 80 women and analyzed 70 completers. Silymarin 140 mg twice daily for 12 weeks, combined with dienogest, reduced pelvic pain on a 0–10 VAS from 7.29 to 4.88, versus 6.73 to 6.61 in the placebo-plus-dienogest group (between-group p = 0.01). IL-6 levels also decreased. However, the authors' claim that silymarin reduced endometrioma size is not well supported: the between-group comparison for lesion volume was not significant (p = 0.24), and the within-group change (p = 0.04 on the right side only) does not establish superiority to placebo. Participant-flow reporting was inconsistent, and the analysis relied on completers rather than intention-to-treat. Clinical interpretation: a pain signal worth replicating, not convincing evidence of lesion regression.

French Maritime Pine Bark (Pycnogenol). A comparative study (Kohama et al., 2007, Journal of Reproductive Medicine) tested Pycnogenol 60 mg/day for 48 weeks against leuprorelin in 58 women after conservative surgery. Symptoms improved gradually with Pycnogenol, though leuprorelin produced greater initial improvement. This study does not appear to have been properly randomized or blinded, and its design does not meet modern RCT standards. A small 2014 study combined pine bark extract with an oral contraceptive and reported improvement, but this also lacks the rigor of a well-designed placebo-controlled trial. Pine bark remains lower-certainty evidence.

Chinese Herbal Formulas. The Cochrane review of Chinese herbal medicine for endometriosis included two RCTs with 158 women. Neither used a placebo comparator; formulas included Nei Yi Wan with some regimens adding herbal enemas. Comparators were gestrinone or danazol. Some symptom outcomes favored herbal treatment, but the absence of placebo control and the heterogeneity of formulas prevent firm conclusions. A 2022 meta-analysis of Chinese medicine combined with dienogest included 12 RCTs and one retrospective study totaling 1,439 participants and reported better combination therapy outcomes. However, pooling heterogeneous formulas with a non-randomized study does not establish the efficacy of any particular reproducible herbal product. A 2025 systematic review and meta-analysis of 16 RCTs reported that acupuncture combined with Chinese herbal medicine significantly increased clinical efficacy rates and reduced VAS pain scores compared to Chinese herbal medicine alone.

Agents with Primary Dysmenorrhea Evidence (Not Endometriosis-Specific)

Ginger. Clinical trials supporting ginger's analgesic effects have primarily enrolled women with primary dysmenorrhea, not endometriosis. The anti-inflammatory and antispasmodic rationale is plausible, but benefits for ordinary menstrual cramps cannot establish efficacy for endometriosis-specific chronic pelvic pain, dyspareunia, or lesion-mediated symptoms.

Peppermint. Similarly, peppermint's clinical evidence comes from primary dysmenorrhea and general antispasmodic studies. These sources do not provide an endometriosis-specific RCT.

Chamomile/Chrysin. Chrysin, a flavonoid found in chamomile, induced apoptosis in endometriotic cells in laboratory models. This is preclinical evidence only. Chamomile tea consumption is not equivalent to a tested concentration of isolated chrysin.

Agents with Primarily Preclinical or Indirect Evidence

Vitex Agnus-Castus (Chasteberry). Studies involve PMS, menstrual irregularity, and luteal-phase dysfunction. Does not establish endometriosis pain relief, lesion regression, or improved fertility outcomes. The claim that Vitex "balances estrogen and progesterone" is too strong a clinical conclusion from the available data.

Ashwagandha. Human studies focus on stress reduction and cortisol modulation. The connection to endometriosis is based on the observation that chronic stress and HPA axis dysregulation coexist with chronic pain conditions. This does not constitute evidence that ashwagandha treats endometriosis or endometriosis-related pain specifically.

Green Tea/EGCG. Epigallocatechin gallate reduced angiogenesis and lesion-related outcomes in experimental models, including effects on VEGF signaling. These are candidate research findings, not demonstrated human clinical benefits for endometriosis.

Boswellia. Anti-inflammatory rationale centers on leukotriene-pathway inhibition. No identifiable endometriosis-specific RCT supports its use for endometriosis pain.

Dong Quai (Angelica sinensis). Traditional use and pharmacologic effects in dysmenorrhea are documented, but evidence is insufficient to recommend it specifically for endometriosis pain or related infertility.

Andrographis/Andrographolide. Reduced lesion volume and hyperalgesia in a rat endometriosis model. Preclinical — not a demonstrated human treatment.

White Peony (Paeonia lactiflora). Animal antispasmodic findings and in-vitro hormonal effects exist, along with an antibody outcome from a multi-herbal formula. Neither an antibody change nor a formula study establishes clinical efficacy of white peony alone.

Safety Considerations. "Natural" does not establish safety. The narrative review by Ilhan et al. (2019) specifically describes toxicity with gossypol, including prolonged amenorrhea and hypokalemia. Herb-drug interactions, hormonal effects, and quality-control variability across botanical products are real clinical concerns. An unsupervised multi-herbal "hormone-balancing" protocol is not defensible practice.

Acupuncture and Related Therapies

Acupuncture has one of the larger bodies of randomized trial evidence among CAIM approaches for endometriosis-associated pain. Network meta-analyses and systematic reviews published in 2024–2025 report pain reduction with acupuncture-related therapies. These reviews overlap and often pool the same trials, many with high risk of bias and few with sham controls, so their combined participant totals are not independent replication. The evidence is positive but of limited certainty.

Network Meta-Analysis Evidence. A 2024 network meta-analysis (Li et al., Journal of Pain Research) included 42 eligible RCTs involving six acupuncture-related interventions and 3,635 participants. On the primary outcome of pain VAS scores, acupuncture was superior to Western medicine (SMD −2.33; 95% CI −4.37 to −0.29), and combination therapy (acupuncture plus pharmacotherapy or herbal medicine) was the most effective approach overall (SMD 1.79; 95% CI 1.21 to 2.41 favoring combination over Western medicine). A 2025 systematic review and NMA in Archives of Gynecology and Obstetrics analyzed 23 RCTs with 1,545 patients and confirmed that acupuncture-related therapies combined with pharmacotherapy were effective for symptomatic endometriosis management.

Acupuncture as Monotherapy. A 2025 systematic review and meta-analysis (Yang et al., Medicine) specifically assessed acupuncture as standalone therapy for endometriosis-related pain, including nine RCTs with 535 patients. Acupuncture monotherapy significantly reduced pain intensity on VAS (mean difference −1.67; 95% CI −2.85 to −0.49; p = 0.006) and improved clinical response rates (OR 2.61; 95% CI 1.38 to 4.95; p = 0.003). No significant differences were seen in serum CA-125 levels; because CA-125 is not a reliable surrogate for lesion regression, this cannot settle whether the disease itself was modified.

Modality Comparisons. The network meta-analysis ranked combination therapy (acupuncture plus pharmacotherapy or herbal medicine) highest for pain VAS scores, serum CA-125 reduction, and clinical response rate. Among acupuncture modalities, electroacupuncture and manual acupuncture had the most evidence. Auricular acupuncture and moxibustion showed promise but had fewer dedicated trials.

ESHRE Positioning. The 2022 European Society for Human Reproduction and Embryology (ESHRE) endometriosis guideline did not recommend any specific nonmedical intervention because the balance of benefits and harms was unclear — not because of an inherently conservative posture or the difficulty of blinding acupuncture trials. Its conclusions reflect the evidence available up to 2022 and should be read alongside, not as a verdict on, the trials published since. Readers should distinguish the guideline's 2022 evidence base from subsequent RCTs and meta-analyses.

Clinical Integration. For the integrative practitioner, the practical takeaway is that acupuncture — particularly in combination with medical therapy — has a credible evidence base for endometriosis-associated pain reduction. It should be presented to patients as an adjunctive modality with meaningful but not guaranteed benefit, not as a standalone replacement for indicated hormonal or surgical management. A trained medical acupuncturist can integrate electroacupuncture and auricular protocols within a coordinated pain management plan, with pain and function tracked against a defined baseline.

Mind-Body and Multidisciplinary Approaches

Endometriosis pain is not purely peripheral. The central sensitization framework helps explain why many patients experience pain disproportionate to visible lesion burden and why comorbid pain conditions (IBS, interstitial cystitis, migraine, vulvodynia) cluster so frequently in this population. Persistent pain after adequate surgery is better understood as multifactorial — residual or deep disease, adhesions, pelvic floor dysfunction, and neuropathic pain are all possible contributors, with central sensitization one among them. Multidisciplinary approaches that address the nervous system's contribution to the pain experience have strong mechanistic justification, even where endometriosis-specific RCTs remain limited.

Pelvic Floor Physiotherapy. Pelvic floor hypertonicity and myofascial dysfunction are common in women with endometriosis. Beyond the general chronic pelvic pain literature, direct endometriosis trials now exist — including Del Forno et al.'s randomized work on pelvic floor physiotherapy and a supervised exercise trial — reporting benefits for specific pain and functional outcomes. A 2024 systematic review on nonpharmacological conservative therapies for chronic pelvic pain also supports physiotherapy approaches such as manual therapy, pelvic floor relaxation training, and trigger-point release, though the evidence base still consists largely of small trials with methodological limitations. Benefits remain intervention- and outcome-specific.

Practically, pelvic floor physiotherapy is one of the most underutilized yet clinically impactful integrative strategies. Many patients with endometriosis have never been assessed for pelvic floor dysfunction despite it being a modifiable contributor to their pain.

Yoga. The ENDOGYM trial (NCT07245537) is a currently registered study evaluating a combined pelvic floor physiotherapy and yoga intervention specifically for endometriosis pain relief. A 2024 pilot study using an endometriosis-specific yoga protocol reported improvements in stress and quality of life, though it used a single-group design without a control arm. Yoga's benefit likely comes through multiple channels: pelvic floor relaxation, parasympathetic upregulation, stress modulation, and improved body awareness. It is a reasonable adjunctive recommendation, best framed as a wellness tool rather than a targeted endometriosis treatment.

Psychological Interventions. These should be assessed individually rather than pooled. Cognitive behavioral therapy (CBT) has the strongest direct evidence: the 2026 HaPPI trial randomized 334 participants and found improved endometriosis-related quality of life with CBT compared to education — a result that warrants separating CBT from yoga, acceptance and commitment therapy (ACT), and mindfulness, each of which rests on weaker or more indirect data. The rationale for psychological approaches is strong given the central sensitization and pain catastrophizing patterns documented in this population. Pain neuroscience education — helping patients understand pain as a nervous system output rather than a direct readout of tissue damage — can reframe the therapeutic relationship and reduce fear-avoidance behavior.

Pain Reprocessing Therapy. Emerging evidence from the broader chronic pain literature supports pain reprocessing therapy (PRT) as a treatment for centrally mediated pain. PRT has not been studied specifically in endometriosis; its relevance here is an extrapolation from other chronic pain conditions to the subset of patients whose pain persists after adequate lesion management, and it should be framed that way. This represents a frontier for integrative endometriosis care.

Relaxation Techniques and Stress Management. Progressive muscle relaxation, diaphragmatic breathing, and biofeedback have all been studied in chronic pelvic pain with modest positive results. Their primary value lies in downregulating sympathetic nervous system activation and reducing the muscular guarding that perpetuates pelvic pain cycles. These should be offered as components of a comprehensive plan, not standalone treatments.

The Microbiome–Estrobolome Axis: Hypothesis vs. Evidence

The gut microbiome has become one of the most popular discussion topics in functional medicine approaches to endometriosis. The hypothesis is mechanistically appealing: gut bacteria that produce β-glucuronidase can deconjugate estrogens in the intestinal lumen, increasing enterohepatic recirculation and raising circulating estrogen levels — potentially feeding estrogen-dependent ectopic tissue. This collection of microbial genes is termed the estrobolome.

A 2025 narrative review in Frontiers in Immunology (Kalopedis et al.) synthesized the literature on microbiome dysbiosis in endometriosis, including altered Bacillota/Bacteroidota ratios, shifts in vaginal community state types, and potential immunomodulatory pathways. A 2025 review in Current Issues in Molecular Biology mapped the estrobolome's role in endometriosis pathogenesis, highlighting β-glucuronidase activity and the connection between dysbiosis and immune dysregulation. A 2026 review in BMC Women's Health (Saponara et al.) evaluated five studies on estrobolome alterations in endometriosis and infertility.

However, the largest metagenomic study to date — from the Estonian Microbiome Cohort, analyzing 1,000 women including 136 with endometriosis (Pérez-Prieto et al., 2024, BMC Medicine) — found no significant differences in alpha or beta diversity, and estrobolome-associated enzyme sequence reads were not significantly different between groups (all FDR p-values > 0.05). The authors concluded that their findings did not provide sufficient evidence to support a gut microbiome-dependent mechanism directly implicated in endometriosis pathogenesis.

This does not close the question. The Estonian study was cross-sectional, used whole-metagenome shotgun sequencing (which is methodologically strong), but could not account for disease stage, hormonal treatment status, or longitudinal microbiome changes. Smaller studies have reported taxa-level differences, but standardization issues across microbiome research — variable sequencing platforms, different bioinformatics pipelines, heterogeneous patient populations — make cross-study comparison unreliable.

Probiotics. It is not accurate to say no probiotic trials exist. Small, preparation-specific placebo-controlled trials have been published: Itoh et al. (2011) on heat-killed Lactobacillus gasseri OLL2809 — which, being heat-killed, should not be equated with a live probiotic — Khodaverdi et al. (2019) on an oral Lactobacillus preparation, and a 2026 randomized pilot in 37 women receiving dienogest that reported benefit with a specific preparation. The appropriate classification is preliminary, preparation-specific clinical evidence — not validation of any commercial product, and certainly not validation of commercial stool testing or an estrogen-detoxification protocol. The ongoing University of São Paulo trial combining a low-FODMAP diet with probiotics may add data, though results are not yet available and its current status is unverified.

Clinical Interpretation. The gut microbiome is a legitimate research frontier in endometriosis. However, the clinical translation gap remains wide. Functional medicine practitioners should avoid presenting microbiome manipulation (via probiotics, prebiotics, or antimicrobial protocols) as a validated endometriosis treatment strategy. Gut health optimization for gastrointestinal comfort is reasonable; claiming that it addresses the root cause of ectopic endometrial tissue growth is not.

Where Root-Cause Claims Overreach

Functional medicine's greatest strength — asking "why" for the individual patient — becomes its greatest liability when the answers run ahead of the evidence. Several widely circulated claims in the integrative endometriosis space deserve direct scrutiny.

"Estrogen Dominance" as a Diagnosis. The term "estrogen dominance" is used freely in functional medicine literature but does not correspond to a validated endocrine diagnosis. Endometriosis is estrogen-dependent — local aromatase activity in lesions is well established. But the clinical leap from "estrogen-dependent disease" to "your estrogen is too high because of poor detoxification, and we can fix it with DIM, calcium-D-glucarate, and cruciferous vegetables" collapses multiple unproven assumptions into a single narrative. Serum estrogen levels do not reliably predict endometriosis severity, local tissue levels are not measurable in clinical practice, and no RCT has demonstrated that reducing circulating estrogen through nutritional interventions produces endometriosis lesion regression.

"Poor Detoxification" as a Root Cause. The framing of endometriosis as a detoxification failure — typically involving the liver, phase I/II biotransformation, and estrogen metabolite ratios — is common in functional medicine circles but is not supported by major endometriosis guidelines (ESHRE, ACOG, NICE). Urinary estrogen metabolite testing (2-OH, 4-OH, 16α-OH ratios) is marketed as a clinical tool but has not been validated as a predictor of endometriosis outcomes or a guide to effective treatment. Interventions targeting these ratios (DIM, I3C, sulforaphane) have mechanistic rationale from cell and animal studies but no endometriosis-specific clinical trial evidence demonstrating symptom improvement or lesion modification.

Symptom Improvement ≠ Lesion Regression. A patient who feels better after a dietary change, supplement protocol, or acupuncture series may be experiencing genuine symptomatic benefit — reduced inflammation, improved gut function, better stress regulation, less central sensitization. None of this necessarily means the endometriotic lesions themselves have regressed. Lesion-focused treatment and symptom-focused treatment answer different clinical questions, and an integrative plan should track separate outcomes: menstrual pain, nonmenstrual pelvic pain, bowel symptoms, sexual pain, daily functioning, medication use, and reproductive goals — not simply a proposed biomarker of "hormone balance."

Functional Testing Limitations. Organic acid testing, comprehensive stool analysis, DUTCH hormone testing, and food sensitivity panels are commonly ordered in functional medicine endometriosis evaluations. While some of these may generate clinically useful information in specific contexts, none has been validated as a diagnostic or treatment-guiding tool for endometriosis in peer-reviewed literature. Over-testing can drive unnecessary interventions, increase patient anxiety, and divert attention from evidence-based management.

The Harm of Delay. Perhaps the most consequential risk of root-cause overreach is the delay of effective treatment. A patient with progressive disease, worsening pain, or time-sensitive fertility goals who spends months on a functional medicine protocol without concurrent gynecologic management may lose valuable time. The integrative clinician's responsibility is coordination, not competition, with established care pathways.

Clinical Decision Framework

The most defensible integrative approach to endometriosis is coordinated gynecologic care plus targeted, evidence-qualified nutritional and multidisciplinary symptom management. The groups below are provisional evidence judgments, not a formal GRADE assessment, and each applies to a specific outcome rather than to an intervention as a whole.

Group 1: Adjunctive interventions with direct clinical evidence — select by symptom, discuss certainty

1. Low-FODMAP diet for prominent GI symptoms (bloating, abdominal pain, altered stool form), dietitian-guided through a structured restriction–reintroduction–personalization process. The EndoFOD crossover trial (35 participants, 60% vs 26% response) is the strongest dietary RCT signal, but it targets GI symptoms, and one small short crossover trial does not establish high-certainty treatment of endometriosis itself.
2. Cognitive behavioral therapy (CBT) for pain-related functioning and quality of life. The 2026 HaPPI trial (334 participants) found improved endometriosis-related quality of life with CBT versus education. Assess CBT on its own evidence, separately from yoga, ACT, and mindfulness.
3. Acupuncture as adjunctive pain therapy. Multiple RCTs and network meta-analyses report pain reduction, but trials vary in quality and comparator, and overlapping meta-analyses pool many of the same trials rather than representing independent replication. Positive but limited-certainty evidence.
4. Pelvic floor physiotherapy and supervised exercise for myofascial dysfunction or pelvic floor hypertonicity. Direct endometriosis RCTs exist (e.g., Del Forno; a supervised exercise trial); benefits are intervention- and outcome-specific.

Group 2: Preliminary, conflicting, or observational evidence — qualified discussion only

1. Vitamin C and E for pain. One 2024 meta-analysis found benefit, but another vitamin meta-analysis found no statistically significant pelvic-pain benefit for the combined C/E subgroup, and a broader placebo-controlled supplement review found no significant pooled pain benefit. These conflicting analyses warrant discussion, not confident recommendation.
2. Nanocurcumin 80 mg/day added to dienogest. One positive small RCT; the contrast with a negative conventional-curcumin trial is consistent with — but does not prove — a bioavailability explanation.
3. Silymarin (milk thistle) 140 mg twice daily added to dienogest. One RCT shows a pain signal; lesion-shrinkage claims are not statistically supported.
4. Selected probiotic preparations. Small, preparation-specific placebo-controlled trials (Itoh 2011, heat-killed; Khodaverdi 2019; a 2026 dienogest-adjunct pilot) report preliminary benefit — not validation of commercial stool testing or detox protocols.
5. MCT-modified ketogenic diet. A 2025 RCT (Naeini et al.; 50 randomized, 44 completed) found between-group improvement in dyspareunia and dyschezia; pelvic pain did not reach significance (p = 0.07), with all attrition in the intervention arm. Preliminary, with substantial limitations.
6. N-acetylcysteine (NAC) 600 mg three times daily on three consecutive days each week (1,800 mg on treatment days). Pain and endometrioma findings are observational only; a postoperative RCT showed no added benefit over continuous oral contraceptives. A phase III RCT is registered; status unverified.
7. Pine bark extract (Pycnogenol). Observational and low-quality comparative evidence; encouraging associations cannot establish efficacy.

Group 3: Benefit not established for the proposed indication, or indirect evidence

1. Conventional curcumin: a triple-blind RCT showed no benefit for the studied regimen and outcomes.
2. Resveratrol: the cited pain trial (40 mg/day added to a contraceptive) showed no pain benefit over the studied period.
3. Omega-3 fatty acids: pooled trials have not established a pain benefit, and heterogeneity is substantial.
4. Vitamin D specifically for endometriosis pain (correct a documented deficiency on its own merits).
5. Mediterranean dietary pattern as a disease-specific therapy — reasonable as a general anti-inflammatory foundation, but not demonstrated to reduce endometriosis pain or lesion burden.
6. Ginger, peppermint, Vitex, ashwagandha, boswellia, EGCG, dong quai, andrographis, white peony: evidence limited to primary dysmenorrhea, preclinical models, or traditional use.
7. Pain reprocessing therapy (PRT): extrapolated from other chronic pain conditions, not studied in endometriosis.

Supplement Sequencing. When patients request a supplement approach, prioritize single-agent trials with defined symptom targets and clear reassessment timelines. Avoid large concurrent supplement stacks that obscure causality. Review interactions and contraindications. Discontinue agents that have not produced meaningful benefit after an adequate trial period.

Outcome Tracking. Separate endpoints are essential: menstrual pain (VAS, 0–10), nonmenstrual chronic pelvic pain, gastrointestinal symptoms (IBS-SSS or equivalent), dyspareunia, dyschezia, daily functional capacity, analgesic/NSAID use, quality of life (EHP-30 or equivalent), and reproductive outcomes when applicable. Do not rely on a single composite marker of "hormone balance" or a proposed biomarker not validated for endometriosis.

When to Refer. Refer urgently or coordinate with gynecology for progressive pain unresponsive to medical therapy, suspected deep infiltrating endometriosis involving bowel or urinary tract, endometrioma larger than 4 cm or growing, active fertility desire with documented endometriosis, and any patient whose integrative plan has not produced meaningful improvement within a reasonable timeframe (typically three to six months for a symptom-directed intervention).

Summary and Future Directions

Integrative and functional medicine can contribute meaningfully to endometriosis care when it stays within the evidence and coordinates with gynecologic management. The strongest contributions today are symptom-directed: the low-FODMAP diet for gastrointestinal symptoms, CBT and acupuncture as adjunctive options with direct trial support, antioxidant vitamin supplementation for pain (where meta-analyses conflict), and multidisciplinary approaches (pelvic floor PT, psychological interventions, pain neuroscience education) for the central sensitization component that conventional lesion-directed treatment often fails to address.

The evidence does not support framing functional medicine as an alternative to hormonal therapy, surgery, or assisted reproduction. No nutritional or botanical protocol has been shown to reliably eradicate endometriotic lesions or reverse endometriosis-related infertility. Symptom improvement and lesion modification are separate outcomes, and the integrative clinician must maintain this distinction in patient communication.

Key Evidence Gaps and Active Research Frontiers

Several registered trials may sharpen the evidence, though their current recruitment status is unverified and none should be cited as confirmed-enrolling. A registered phase III NAC RCT (Royan Institute) is designed to provide double-blind placebo-controlled data on NAC and IVF/ICSI outcomes in endometrioma patients. A University of São Paulo trial combining a low-FODMAP diet with probiotics in women with endometriosis and IBS is intended to test whether microbiome modulation adds benefit beyond fermentable carbohydrate restriction alone. The ENDOGYM protocol testing combined pelvic floor physiotherapy and yoga would provide structured data on an intervention often recommended without dedicated trial support.

The nanocurcumin finding — positive results with a bioavailable formulation where conventional curcumin failed — highlights the critical importance of pharmacokinetic considerations in botanical medicine research. Future trials should specify formulation, bioavailability data, and plasma levels rather than treating "curcumin" as a single entity.

The gut microbiome–estrobolome axis remains a compelling hypothesis, but the largest metagenomic cohort to date did not support the measured stool microbiome and estrobolome associations — a negative observational finding, not a definitive causal experiment. Longitudinal studies with disease-stage stratification, standardized sequencing protocols, and functional metabolomic analysis (rather than taxonomic composition alone) are needed before microbiome-based endometriosis interventions can be recommended.

Toward Precision Integrative Care

A 2025 systematic review in Frontiers in Endocrinology on endometriosis-associated infertility emphasized multi-omics integration — hormonal, immune-inflammatory, oxidative stress, genetic/epigenetic, and microbiome/metabolic — as the pathway toward precision therapeutics. The functional medicine framework aligns conceptually with this vision, but the field must resist the temptation to treat mechanistic models as validated clinical protocols before the confirming trials exist.

The most important contribution integrative medicine can make right now is not a new supplement protocol — it is a coordinated care model that ensures no patient falls through the gap between gynecologic management and the lived experience of chronic pain, gastrointestinal distress, fatigue, and reproductive uncertainty that defines daily life with endometriosis.

Yoon Hang Kim, MD, MPH, is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and the founder of the LDN Support Group.

Sources

• Varney et al. (2025). Effect of a 28-day low FODMAP diet on gastrointestinal symptoms associated with endometriosis (EndoFOD). Alimentary Pharmacology and Therapeutics. DOI: 10.1111/apt.70161.
• Bayu & Wibisono (2024). Vitamin C and E antioxidant supplementation for endometriosis pain. PLOS ONE, 19(5):e0301867.
• Xu et al. (2023). Antioxidant vitamins supplementation reduce endometriosis-related pelvic pain. Reproductive Biology and Endocrinology, 21:79.
• Li et al. (2024). Acupuncture and related therapies for endometriosis: a network meta-analysis. Journal of Pain Research, 17:3197–3216.
• Yang et al. (2025). Acupuncture monotherapy for endometriosis-related pain. Medicine, 104(34):e44005.
• Wang et al. (2025). Acupuncture-related therapies for symptomatic endometriosis: NMA. Archives of Gynecology and Obstetrics, 311(3):697–714.
• Xu et al. (2025). Acupuncture combined with CHM for endometriosis-associated pain. Frontiers in Medicine, 12:1649980.
• Sargazi-Taghazi et al. (2025). Nanocurcumin for endometriosis pain. Phytomedicine. DOI: 10.1016/j.phymed.2025.156715. PMID: 40220411.
• Gudarzi et al. (2024). Conventional curcumin for endometriosis. Phytotherapy Research, 38:147–155. PMID: 37818734.
• Mirzaei et al. (2022). A randomized trial assessing the efficacy of silymarin on endometrioma-related manifestations. Scientific Reports, 12:17549. DOI: 10.1038/s41598-022-22073-8. PMID: 36266431.
• da Silva et al. (2017). Resveratrol for endometriosis pain. Journal of the Endocrine Society, 1(4):359–369.
• Omega-3 PUFAs for endometriosis: meta-analysis (2025). Clinics, 80:100654. PMID: 40273491.
• Anastasi et al. (2023). NAC for endometriosis (600 mg three times daily, three days/week × 3 months). International Journal of Environmental Research and Public Health, 20(6):4686.
• Watrowski et al. (2026). N-Acetylcysteine in Endometriosis: A Systematic Review of Biological Rationale and Clinical Evidence. Antioxidants, 15(7):880. DOI: 10.3390/antiox15070880. PMID: 42510611.
• Naeini et al. (2025). MCT-modified ketogenic diet as an adjunct in endometriosis: a 12-week RCT. BMC Women's Health, 25:232. DOI: 10.1186/s12905-025-03798-w.
• HaPPI trial (2026). CBT versus education for endometriosis-related quality of life (334 participants). PMID: 41717450.
• Itoh et al. (2011). Lactobacillus gasseri OLL2809 (heat-killed), randomized placebo-controlled trial in endometriosis.
• Khodaverdi et al. (2019). Oral Lactobacillus preparation: pilot placebo-controlled RCT in endometriosis.
• 2026 randomized probiotic pilot (37 women on dienogest) — reported benefit with a specific preparation.
• Del Forno et al. Pelvic floor physiotherapy RCT in endometriosis (see PMC10818504).
• Pérez-Prieto et al. (2024). Gut microbiome in endometriosis: 1,000-person cohort. BMC Medicine, 22:294.
• Kalopedis et al. (2025). Microbiome in endometriosis. Frontiers in Immunology, 16:1631522.
• De Araugo et al. (2025). Nutrition interventions in endometriosis: scoping review. Journal of Human Nutrition and Dietetics, 38(1):1–16. DOI: 10.1111/jhn.13411.
• Barrea et al. (2025). Medical nutrition therapy for obesity and endometriosis. Current Obesity Reports, 14:68.
• Scoping review: CAIM for endometriosis pain and QoL (2025). PMID: 41160417. (A scoping review maps the literature; it does not establish treatment certainty.)
• Ilhan et al. (2019). Novel Drug Targets with Traditional Herbal Medicines for Overcoming Endometriosis. PMC 6637095.
• Kohama et al. (2007). Pycnogenol for endometriosis: comparative study. Journal of Reproductive Medicine, 52:703–708. PMID: 17879831.
• ESHRE Guideline: Endometriosis (2022). European Society for Human Reproduction and Embryology.
• Institute for Functional Medicine. Endometriosis & Lifestyle-Based Therapies (educational webpage; full title, URL, and access date to be added — not used as primary efficacy evidence).
• Citations pending full verification: the Kerman University curcumin dysmenorrhea trial (2025), Saponara et al. (2026, BMC Women's Health) estrobolome review, the 2025 Frontiers in Endocrinology multi-omics review, the endometriosis yoga pilot, and the 2024 psychological-intervention and physiotherapy reviews require complete bibliographic confirmation before publication. Trial recruitment statuses (NCT05460858; São Paulo probiotic trial; ENDOGYM) are unverified and should not be presented as actively enrolling.